Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab

Abstract To compare outcomes in patients with human epidermal growth factor receptor-2 (HER2)-positive breast cancer who received either dose-dense neoadjuvant chemotherapy (NAC) with trastuzumab or standard-interval chemotherapy with trastuzumab. Patients with HER2-positive breast cancer who receiv...

Full description

Bibliographic Details
Main Authors:	Lize Wang, Yang Zhang, Yingjian He, Jinfeng Li, Tianfeng Wang, Yuntao Xie, Zhaoqing Fan, Tao Ouyang
Format:	Article
Language:	English
Published:	Nature Portfolio 2021-06-01
Series:	npj Breast Cancer
Online Access:	https://doi.org/10.1038/s41523-021-00284-y

Similar Items

Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
by: Xing Wang, et al.
Published: (2024-11-01)

Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
by: Emanuela Ferraro, et al.
Published: (2022-03-01)

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors
by: I.P.C. Buzatto, et al.

Pathological complete response in early stage HER-2 positive breast cancer patients, receiving neoadjuvant chemotherapy/ Trastuzumab, in a single breast unit in Johannesburg
by: A. Bellomo, et al.
Published: (2021-04-01)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
by: Izzet Dogan, et al.
Published: (2023-05-01)

Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study
by: Lu Liu, et al.
Published: (2023-12-01)

Pathological Complete Response with Neoadjuvant Trastuzumab Combined with Chemotherapy in HER2 Positive Breast Cancer: A Single Institution Retrospective Analysis from Vietnam
by: Phung HT, et al.
Published: (2020-10-01)

Real-world Research of Trastuzumab and Pertuzumab Combined with Chemotherapy in Neoadjuvant Treatment of HER2-positive Breast Cancer
by: MA Xiangmin, et al.
Published: (2022-01-01)

A multicenter single‐arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2‐positive breast cancer
by: Qiyun Shi, et al.
Published: (2023-12-01)

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2019-12-01)

Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report
by: Wang Jun, et al.
Published: (2010-09-01)

Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy
by: Yehoda M. Martei, et al.
Published: (2022-05-01)

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer
by: Samuel A. Jacobs, et al.
Published: (2020-01-01)

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer
by: Yi Xiao, et al.
Published: (2022-05-01)

Lapatinib, trastuzumab or the combination added to neoadjuvant chemotherapy for breast cancer
by: Quan Liang, et al.
Published: (2016-10-01)

Neoadjuvant Trastuzumab and Pertuzumab in Combination with Standard Chemotherapy for HER2-Positive Early Breast Cancer: Real-World Practice in Cuba
by: Elías A. Gracia Medina, et al.
Published: (2023-01-01)

The Relationship of Pathological Response and Visceral Muscle and Fat Volume in Women With Breast Cancer Who Received Neoadjuvant Chemotherapy
by: Tuba Kayan Tapan, et al.
Published: (2024-04-01)

In situ HER2 RNA expression as a predictor of pathologic complete response of HER2-positive breast cancer patients receiving neoadjuvant chemotherapy and anti-HER2 targeted treatment
by: Huang-Chun Lien, et al.
Published: (2024-06-01)

Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer
by: Cláudia Vieira, et al.
Published: (2023-01-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Cardiac function in women receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer
by: Jamal Zekri, et al.
Published: (2023-05-01)

Case report: Patients with positive HER-2 amplification locally advanced gastroesophageal junction cancer achieved pathologic complete response with the addition of pembrolizumab to chemotherapy plus trastuzumab as neoadjuvant therapy
by: Huanhuan Li, et al.
Published: (2025-02-01)

Pathologic Complete Response of HER-2 Neu-Positive Invasive Ductal Carcinoma and Ductal Carcinoma In Situ following Neoadjuvant Chemotherapy plus Trastuzumab: A Case Report and Review of Literature
by: Sommer R. Gunia, et al.
Published: (2012-01-01)

Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
by: Guoshuang Shen, et al.
Published: (2021-07-01)

Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study
by: Haoqi Wang, et al.
Published: (2022-07-01)

Neoadjuvant Trastuzumab Concurrent with Nonanthracycline-based Regimens for HER2-positive Locally Advanced Breast Cancer
by: Wei-Hsin Liu, et al.
Published: (2014-09-01)

Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy
by: Yingbo Shao, et al.
Published: (2024-02-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)

Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
by: Hong-Fei Gao, et al.
Published: (2021-04-01)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
by: Luca Gianni, et al.
Published: (2022-01-01)

The value of artificial intelligence-assisted technology in HER2 assessmentof gastric cancer patients receiving neoadjuvant chemotherapy
by: LIU Yang, HU Yiyang, LIU Yueping, NIU Shuyao, DING Pingan, TIAN Yuan, GUO Honghai, YANG Peigang, ZHANG Ze, ZHENG Tao, TAN Bibo, FAN Liqiao, LI Yong, ZHAO Qun
Published: (2023-04-01)

Survival outcomes of locally advanced gastric cancer cases with pathological complete response received neoadjuvant chemotherapy
by: Qing Hu, et al.
Published: (2021-06-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

Adapted Physical Activity for Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Trastuzumab Against HER2 (APACAN2): A Protocol for a Feasibility Study
by: Angeline Ginzac, et al.
Published: (2021-12-01)

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression
by: Mao Shang, et al.
Published: (2022-01-01)

Association of Various Factors in Terms of Pathological Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy
by: Anum Zargham, et al.
Published: (2023-05-01)

Complete pathological response in patients with locally advanced cancer of breast and positive Her2/neu with neoadjuvant chemotherapy
by: de Torraza Idalmis, et al.
Published: (2007-02-01)

Pathological Complete Response to Neoadjuvant Chemotherapy in a Patient with HER2-Positive Squamous Cell Carcinoma of the Breast
by: Yuki Usui, et al.
Published: (2021-10-01)

Feasibility of using negative ultrasonography results of axillary lymph nodes to predict sentinel lymph node metastasis in breast cancer patients
by: Xue Chen, et al.
Published: (2018-07-01)